Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan

Inclusion Criteria: * Patients with advanced malignant solid tumors * ECOG Performance Status of ≤ 2 * Patients must have the following laboratory values: * Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L, Hemoglobin (Hgb) ≥ 8.5 g/dl, Platelets (plt) ≥ 100 x 109/L * Potassium, Calcium, Magnesium, Phosphorus within normal limits or correctable with supplements * AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN) * Serum bilirubin ≤ 1.5 x ULN, Serum albumin \> 2.5g/dl, Serum creatinine≤ 1.5 x ULN or 24-hour clearance ≥ 50 ml/min * Able to sign informed consent and to comply with the protocol Exclusion Criteria: * Patients with brain metastasis. * Prior treatment with any HSP90 or HDAC inhibitor compound. * Treatment with therapeutic doses of coumarin anticoagulants. * Pregnant and lactating women. * Severe and/or uncontrolled acute or chronic liver disease * Severe and/or uncontrolled acute or chronic renal disease * Chronically significant heart disease * History (or family history) of long QT syndrome. QTc ≥ 450 msec on screening ECG, ischemic heart disease, heart fail, ECG abnormalities, atrial fibrillation, atrial flutter or ventricular arrhythmias including ventricular tachycardia or Torsades de Pointes. * Patients who are currently receiving treatment with any medication which has a relative risk or prolonging the QTcF interval or inducing Torsades de Pointes * Patients with known disorders due to a deficiency in bilirubin glucuronidation (e.g Gilbert's syndrome). Other protocol-defined inclusion/exclusion criteria may apply